{"DataElement":{"publicId":"7847212","version":"1","preferredName":"Lorlatinib Agent Delay Administered Dose Indicator","preferredDefinition":"An indicator of whether or not the Lorlatinib agent dose was delayed.","longName":"LORLB_DS_ADMR_HLD_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7847211","version":"1","preferredName":"Lorlatinib Agent Delay Administered","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later._The act of having given something (e.g., a medication or test).","longName":"6199780v1.0:7588093v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6199780","version":"1","preferredName":"Lorlatinib Agent","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C113655:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorlatinib","conceptCode":"C113655","definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FC2277-BA3F-2DAE-E053-F662850AC025","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7588093","version":"1","preferredName":"Delay Administered","preferredDefinition":"Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.:The act of having given something (e.g., a medication or test).","longName":"C25476:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delay","conceptCode":"C25476","definition":"Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC47CA80-E1E5-07C5-E053-4EBD850A007D","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D21A3B2C-1DE1-3555-E053-4EBD850AC19C","latestVersionIndicator":"Yes","beginDate":"2021-12-01","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-12-01","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2952984","version":"1","preferredName":"Dose Indicator","preferredDefinition":"the indicator for the amount of medicine taken, or radiation given, at one time.","longName":"2952984v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes, unplanned per protocol","valueDescription":"Yes, unplanned per protocol","ValueMeaning":{"publicId":"2952985","version":"1","preferredName":"Yes, unplanned per protocol","longName":"2952985","preferredDefinition":"Yes, unplanned per protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52FC-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5315-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"Yes, planned per protocol","valueDescription":"Yes, planned per protocol","ValueMeaning":{"publicId":"2952986","version":"1","preferredName":"Yes, planned per protocol","longName":"2952986","preferredDefinition":"Yes, planned per protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-531F-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5338-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5342-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5682946","version":"1","preferredName":"Not Applicable","longName":"5682946v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9B2B-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":"2023.8.15 Alt VM added per ticket request CADSR0002731. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6BAB45A-987B-42A8-E053-4EBD850A5197","beginDate":"2020-05-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6BAB45A-9886-42A8-E053-4EBD850A5197","beginDate":"2020-05-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2952983","version":"1","preferredName":"Dose Indicator","preferredDefinition":"The amount of medicine taken, or radiation given, at one time.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C25488:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52D6-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52E7-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ZHANGWE","dateModified":"2020-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Was Lorlatinib held?","type":"Preferred Question Text","description":"Was Lorlatinib held?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Was Lorlatinib held during this reporting period?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D21AA14F-8256-0273-E053-4EBD850A1098","latestVersionIndicator":"Yes","beginDate":"2021-12-01","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-12-01","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}